A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Study of Anti CTLA-4 Antibody SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

To evaluate the efficacy of SHR-8068 combined with Adebrelimab and Bevacizumab compared with Sintilimab combined with Bevacizumab for the first-line treatment of advanced HCC

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Able and willing to provide a written informed consent

• ≥ 18 years old, both male and female

• Unresectable locally advanced or metastatic HCC confirmed by histopathologically/cytologically

• At least one measurable lesion based on RECIST v1.1 criteria

• Barcelona clinic liver cancer: Stage B or C

• No previous systemic antitumor therapy for HCC

• ECOG PS of 0-1

• Child-Pugh score of A or B7

• Expected survival period ≥ 12 weeks

⁃ Adequate organ function

⁃ Blood pregnancy negative (women of childbearing age) and non-breastfeeding, effective contraception

Locations
Other Locations
China
Anhui Provincial Hospital
RECRUITING
Hefei
Contact Information
Primary
Xin Shi
xin.shi.xs3@hengrui.com
0518-82342973
Backup
Ying Sun
ying.sun.ys1@hengrui.com
0518-82342973
Time Frame
Start Date: 2024-10-28
Estimated Completion Date: 2030-12-31
Participants
Target number of participants: 590
Treatments
Experimental: SHR-8068 combined with Adebrelimab and Bevacizumab
Active_comparator: Sintilimab combined with Bevacizumab
Related Therapeutic Areas
Sponsors
Leads: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

This content was sourced from clinicaltrials.gov